Clinical trials: Influenza
Influenza, Human, Infections
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine.
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05875961
- Testing
- Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59
- Where
- 7 sites in United States, Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60…
- Trial name
- NCT02269852
- Testing
- trivalent seasonal influenza vaccine
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
1. To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level delivered i.m., or the 2.0 µg dose level delivered s.c.
- Trial name
- NCT00921947
- Testing
- VAX102
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age
This study will evaluate the safety and immunogenicity of different combinations of influenza vaccine in healthy young children.
- Trial name
- NCT00848887
- Testing
- Adjuvanted and un-adjuvanted influenza vaccines
- Where
- Belgium
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza in Humans
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy…
- Trial name
- NCT02888327
- Testing
- AL-794, Oseltamivir, Digoxin
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Prophylaxis of Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season
Annual study to investigate influenza vaccine (flu vaccine) developed for the 2012/2013 season for the prevention of influenza infection. The immunizing effect is being investigated, as well as its tolerability and safety.
- Trial name
- NCT01633749
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza
Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)
The clinical trial was designed to evaluate the immunogenicity and safety against pediatric Inactivated influenza vaccine (Split Virion) (0.25ml formulation) of Hualan administered on infants age 6 months to 36 months.
- Trial name
- NCT01554826
- Testing
- Influenza Split Vaccine, Inactivated Influenza Vaccine
- Where
- China
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an…
- Trial name
- NCT05650554
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Relapsing Remitting Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.
- Trial name
- TODAY (NCT00574041)
- Testing
- Interferon beta-1a
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Biogen
Influenza
Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
- Trial name
- NCT07291635
- Testing
- Recombinant Influenza vaccine candidate, Commercial Influenza vaccine
- Where
- 7 sites in Canada
- Volunteers
- 728 people, healthy volunteers welcome
- Sponsor
- Aramis Biotechnologies Inc.
Influenza
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
As a result of the recent supply shortages in the U.S., as well as an anticipated increase in demand during the coming years, GSK Biologicals is pursuing licensure of Fluarix in the U.S.
- Trial name
- NCT00197223
- Testing
- Influenza vaccine
- Where
- Czechia
- Volunteers
- 6,213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years
- Trial name
- NCT00374842
- Testing
- Fluarix™, GSK1247446A
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population.
- Trial name
- NCT00517517
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Breast Neoplasms, Neoplasm Metastasis
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast…
- Trial name
- NCT05600582
- Testing
- CodaLytic
- Where
- 2 sites in United States
- Sponsor
- Codagenix, Inc
Influenza, Human
Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males
This study is a randomized, double-blind, ascending dose, placebo-controlled, incomplete crossover, single and multiple dose study in healthy Japanese male subjects to assess the pharmacokinetics and safety/tolerability of single…
- Trial name
- NCT01428479
- Testing
- GR121167 Solution
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza
The purpose of this study is to compare the safety profile in healthy volunteers of a single intravenous administration of TCN-032 as compared with placebo.
- Trial name
- NCT01390025
- Testing
- TCN-032
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theraclone Sciences, Inc.
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial…
- Trial name
- NCT05972174
- Testing
- mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
- Trial name
- NCT01003418
- Testing
- GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar
- Where
- 4 sites in Norway
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline